Why ALT fell on Nov 12
Down 17% on Nov 12 while the S&P 500 fell 0.4%.
- Its Nov 12 results:
−3Long-term trend
Down 17% on Nov 12 while the S&P 500 fell 0.4%.
−3Long-term trend
ALT's Quality Score rose 4 points on Fri, Nov 13, to -1. Jerome Benedict Durso (President and CEO) bought $50K on Nov 13, filed Nov 13, and 2 more filings.
Follow ALT's trial news. Pro members can get an alert when Altimmune files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 129.6% more shares than a year ago |
| Latest filing | 8-K, Nov 12 |
ALT closed +1.9% that day.
1 more big story on ALT in the past 12 months, for Pro members.
After its last 4 reports it closed -9.7% on average, higher 0 of 4 times.
About 18 quarters
Director Wayne Pisano bought 10,000 shares on Nov 13. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ALT is #152 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 152 |
Cash and short-term investments: ALT $265M, GPCR $1.24B, MBX $482M.
Expected to report Thu Mar 4, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.15 a share, from $0.21.
“The increase was driven primarily by an increase in compensation expenses and professional services”
ALT's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -1.6% | -16.6% | not yet |
| Aug 12, 2026 | +1.7% | -2.3% | -1.0% |
| May 13, 2026 | -3.3% | -1.9% | -11.0% |
Sales grew in three of the last five years, to $41K in 2025. It lost money in each of the seven years.
RSI 26.5, MACD below signal, below both averages. Not scored.
3 insiders bought $126K across 4 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ALT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
“The biopharmaceutical industry is intensely competitive and is characterized by rapid technological progress.”
ALT scores -1 today, which Breakaway calls Poor. It is #152 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 17% on Nov 12 while the S&P 500 fell 0.4%. Cash lasts about 18 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ALT scores -1 today, which Breakaway calls Poor (below zero). That is #152 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ALT's -1.
3 insiders bought $126K across 4 filings in the last 6 months. No open-market sales on record. The newest is Jerome Benedict Durso, President and CEO, who bought $50K on Nov 13. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.